Rockefeller Capital Management
PTGX icon

Rockefeller Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Rockefeller Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Sell
4,818
-10
-0.2% -$1.04K ﹤0.01% 2000
2026
Q1 		$509K Buy
4,828
+1,536
+47% +$136K ﹤0.01% 1964
2025
Q4 		$288K Buy
3,292
+312
+10% +$25.5K ﹤0.01% 2180
2025
Q3 		$198K Buy
+2,980
New +$169K ﹤0.01% 2240
2020
Q4 		– Sell
-2,000
Closed -$39K – 2983
2020
Q3 		$39K Hold
2,000
– – ﹤0.01% 1587
2020
Q2 		$35K Buy
+2,000
New +$25.1K ﹤0.01% 1506

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rockefeller Capital Management's PTGX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 0.21% in Q2 2026, selling an estimated $1.04K and leaving 4,818 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

Rockefeller Capital Management first reported a position in PTGX in Q2 2020 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Rockefeller Capital Management held 4,818 shares of Protagonist Therapeutics worth $591K as of Q2 2026.
  • Rockefeller Capital Management sold 10 Protagonist Therapeutics shares in Q2 2026, an estimated $1.04K.
  • Protagonist Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2000 holding.
  • Rockefeller Capital Management first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.